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INTRODUCTION:
Epithelial ovarian cancer (EOC) is the most lethal gynecological tumor. Ovarian cancer (OC) is the fifth most common type cause of cancer in women [1] and the fourth most common cause of cancer death in women [2] . High-grade serous carcinoma (HGSC) comprises approximately 70% of all EOC and accounts for the majority of deaths. HGSC is an aggressive neoplasms, presents in advanced stages (III-IV) and has a high frequency of TP53 mutations [3, 4] . This suggests that there may be other tumor microenvironment or host characteristics with a dominant role in survival.
To date, the standard therapy for advanced ovarian cancer is cytoreductive surgery or debulking surgery, followed by chemotherapy with the combination of carboplatin (area under the curve (AUC), 5.0-7.5) and paclitaxel 175 mg/m 2 every 3 weeks, for 6 cycles) [5] or three cycles of platinumbased neoadjuvant (NACT), followed by interval debulking surgery, and then at least three more cycles of platinum-based chemotherapy [6] .
In recent years, there has been interest in understanding the role of immune response. Ovarian cancer is an immune reactive malignancy with a complex immune suppressive network that blunts successful immune eradication. This suppressive microenvironment may be mediated by recruitment or induction of CD4+ regulatory T cell (Tregs) [7] .
A number of studies have demonstrated that the presence of tumor-infiltrating lymphocytes (TIL) in surgically resected tumor tissue correlates with a favorable prognosis, especially in HGSC. Landmark study by Coukos et al. , retrospective analysis of 186 stage III-IV EOC patients revealed that the 5-year overall survival (OS) rate was 38% for patients with CD3+ TIL-positive tumors, compared with only 4.5% for CD3+ TIL-negative tumors [8, 9] . Other studies revealed that the CD8+ subset of TIL correlates more strongly with survival [10] [11] [12] [13] .
Tregs are a heterogeneous CD4+ T cell subpopulation whose primary function is to immunoregulate by blocking the function of activated T cells. CD4+ Tregs can be divided into two main subsets: naturally occurring Tregs with a CD4+CD25+ forkhead box P3 (FOXP3)+ phenotype and induced Tregs with a variable CD25 expression [14] . Curiel et al. initially showed a strong association of CD4+CD25+ T cell with poor survival [15] .
The expression of PD-L1 in a range of malignancies including renal, esophageal and colorectal cancers, suggesting that some tumors have evolved high levels of expression of this molecule, possibly suppressing anti-tumor T cell responses [16, 17] . As a result, PD-L1 offers potential as a prognostic marker as well as being a target for therapy.
Hamanishi et al. studied expression of PD-L1 and PD-L2 on ovarian tumors of different grades and found a significantly worse overall survival in patients whose tumor expressed one or both of these ligands. They also showed an inverse correlation between PD-L1 expression and intraepithelial CD8 count, a known prognostic marker [18] [19] [20] .
The discovery of the importance of the immune system in the development of cancer can help us in the determination of new diagnostic and prognostic parameters and the possibility of using serum markers instead of biopsies. This evades the possibility of non-representative biopsies, intermetastasesheterogeneity and might be able to avoid invasive diagnostic techniques [21, 22] .
The purpose of this study was to assess the variation of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes expression in stage IIIc/IV of high-grade serous ovarian carcinoma, and prognostic value.
MATERIALS AND METHODS: Patients and samples
The person directing the project identified those patients whose diagnosis was proven to be HGSC, stage III-IV (FIGO), underwent primary debulking surgery (PDS) and postchemotherapy residual disease and requested them to participate in the study.
analysis demonstrated that the expression of epithelial CD3 ≤ 4, 3 in pre-surgery samples is a marker of poor prognosis.
Conclusion:
The high number of tumor-infiltrating lymphocytes in post-surgery samples was significantly associated with higher rates of complete pathological response and better prognosis. It is convenient to carry out further and multicentric studies to validate these results. The study design will be Descriptive Observational: Population 
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Fresh tumor biopsies
Omental biopsies were collected in the operating room from untreated patients undergoing PDS or diagnostic laparoscopy and from patients undergoing IDS after NACT and fresh-frozen samples were histologically matched to FFPE specimens of the same patient by hematoxylin and eosin review.
Immunohistochemistry
Immunohistochemistry was performed on 4 μm-thick sections of formalin-fixed, paraffin-embedded tissue samples 
Statistical analysis
Mann-Whithney tests were done to compare the percentage of infiltrated lymphocytes between the sample before and the sample after chemotherapy. Analyses were done using GraphPad Prism. We make response prediction models with infiltration percentages but no significant results have been obtained.
Values of CD3+, CD4+ and CD8+ TL as general predictors of pathological response (pCR) were performed using an ROC curve and the confidence interval (95% CI) of the area under the curve; in the case that was significant an approximate cutoff point was made.
The risk estimate for complete pathological response of TILs was calculated using the Odds-ratio (OR) and for the overall survival (OS), the estimated Hazard Ratios (HR) with their 95% CIs were estimated. In all cases a type I error of 0.05% is considered.
RESULTS
Patient's characteristics
We retrospectively identified 33 patients diagnosed with The cells infiltrating tumor islets) predicts significantly longer survival in ovarian cancer [23] [24] [25] .
We demonstrate that the effect of NACT on a human metastatic tumor microenvironment induces activation of CD3+ T cells, CD4+ T cells and CD8+ T cells. Importantly, even those patients who had a poor response to three cycles of platinum-based chemotherapy had a high number of CD8+ T cells.
Our findings are supported by a previous study reporting an association of CD8+ T cells and tumor eradication and concurrent activation CD4+ T cells is required to support potent cytotoxic T lymphocytes [26] [27] [28] [29] [30] [31] . A high number of tumor infiltrating cytotoxic T lymphocytes was associated with a better overall survival, presumably due to the stronger effect in non-optimally debulked patients [32] . with prolonged survival, and viceversa the association of immune escape mechanisms with poor survival, suggest that ovarian cancers are intrinsically immunogenic [35] .
The presence or absence of T cells in solid tumors is a key limiting factor for cancer immunotherapy [23] and the presence of CD8+ T cells at the invasive margin was predictive of response.
CONCLUSION
The high number of tumor-infiltrating lymphocytes in post-surgery samples was significantly associated with higher rates of complete pathological response and better prognosis.
So, the incorporation of immunotherapies to postchemotherapy treatment options could be of benefit for prolonged disease control in patients with advanced HGSC. It is convenient to carry out further and multicentric studies to validate these results. 
Conflict of
